Asian Value Stocks Priced Below Estimated Intrinsic Values
As global markets face volatility due to renewed tariff threats and shifting economic policies, investors are increasingly turning their attention to Asia, where opportunities for value investing remain robust. In this environment, identifying stocks priced below their estimated intrinsic values can be a strategic approach for those seeking potential long-term growth in the Asian market.
Name
Current Price
Fair Value (Est)
Discount (Est)
Pansoft (SZSE:300996)
CN¥14.23
CN¥28.32
49.8%
Xiamen Amoytop Biotech (SHSE:688278)
CN¥77.56
CN¥153.79
49.6%
Fuji (TSE:6134)
¥2247.00
¥4481.26
49.9%
H.U. Group Holdings (TSE:4544)
¥3062.00
¥6058.85
49.5%
Shenzhen Yinghe Technology (SZSE:300457)
CN¥17.28
CN¥34.50
49.9%
Devsisters (KOSDAQ:A194480)
₩38500.00
₩76148.72
49.4%
TLB (KOSDAQ:A356860)
₩17600.00
₩34842.86
49.5%
Heartland Group Holdings (NZSE:HGH)
NZ$0.80
NZ$1.58
49.3%
BalnibarbiLtd (TSE:3418)
¥1162.00
¥2310.67
49.7%
J&T Global Express (SEHK:1519)
HK$6.65
HK$13.21
49.7%
Click here to see the full list of 307 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
We'll examine a selection from our screener results.
Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea, with a market cap of ₩4.66 trillion.
Operations: PharmaResearch Co., Ltd. focuses on biopharmaceutical operations primarily within South Korea.
Estimated Discount To Fair Value: 24.7%
PharmaResearch is trading at approximately 24.7% below its estimated fair value of ₩596,088.91, with a current price of ₩449,000. The company's earnings are forecast to grow significantly at 25.85% annually over the next three years, outpacing the Korean market average of 20.5%. Revenue growth is also expected to be robust at 24.4% per year, surpassing the market's 7.4%, highlighting its potential as an undervalued cash flow opportunity in Asia.
Our comprehensive growth report raises the possibility that PharmaResearch is poised for substantial financial growth.
Take a closer look at PharmaResearch's balance sheet health here in our report.
Overview: Hyosung Heavy Industries Corporation manufactures and sells heavy electrical equipment both in South Korea and internationally, with a market cap of ₩5.67 trillion.
Operations: Hyosung Heavy Industries generates revenue primarily through the manufacturing and sale of heavy electrical equipment domestically and abroad.
Estimated Discount To Fair Value: 26.6%
Hyosung Heavy Industries is trading at approximately 26.6% below its estimated fair value of ₩829,765.66, with a current price of ₩609,000. The company's earnings are projected to grow significantly at 21.94% annually over the next three years, exceeding the Korean market's growth rate of 20.5%. Although revenue growth is slower than desired at 9.8%, it still surpasses the market average of 7.4%, positioning it as an undervalued cash flow opportunity in Asia.
Our growth report here indicates Hyosung Heavy Industries may be poised for an improving outlook.
Click here and access our complete balance sheet health report to understand the dynamics of Hyosung Heavy Industries.
Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩7.11 trillion.
Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, amounting to ₩578 billion.
Estimated Discount To Fair Value: 48.4%
SK Biopharmaceuticals is trading at ₩90,800, significantly below its estimated fair value of ₩176,112.28, presenting a potential undervalued cash flow opportunity. Despite earnings growth forecasted at 18% annually—slightly below the Korean market's 20.5%—revenue is expected to increase by 22.8% per year, outpacing the market average of 7.4%. The company recently became profitable and anticipates high future returns on equity at 32.5%.
Upon reviewing our latest growth report, SK Biopharmaceuticals' projected financial performance appears quite optimistic.
Get an in-depth perspective on SK Biopharmaceuticals' balance sheet by reading our health report here.
Take a closer look at our Undervalued Asian Stocks Based On Cash Flows list of 307 companies by clicking here.
Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A214450 KOSE:A298040 and KOSE:A326030.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Red Lobster's 36-year-old CEO started as a Goldman Sachs intern. He reveals 3 bold moves he's cooking up for the seafood chain's comeback
Red Lobster CEO Damola Adamolekun came from a private equity and finance background, breaking into the restaurant industry through a successful deal he navigated. The former P.F. Chang's CEO outlined the changes he's enacting to save the beleaguered seafood chain from bankruptcy and to make it the beloved brand it once was. Damola Adamolekun reached the pinnacle of restaurant leadership in a somewhat unconditional way. Although the Red Lobster CEO waited tables back in high school, his first big career move was landing an internship with global investment bank Goldman Sachs at age 19. At the time, Adamolekun was a student athlete at Brown University, where he studied economics and political science. He continued to work as an analyst with Goldman Sachs following graduation for a couple of years, then moved on to become a private equity associate with TPG Capital, where he worked until 2015. But Adamolekun's big break came while he was a partner at hedge fund Paulson & Co., which now operates as a family office. In 2019, Paulson purchased Asian-inspired restaurant chain P.F. Chang's in a $700 million deal. Adamolekun said during a podcast episode of The Breakfast Club that he was the one who pitched the idea to buy P.F. Chang's to the firm. 'I thought we could do a lot of new things with it. We could add delivery, we could remodel the restaurants. We could make it more interesting,' Adamolekun said. The deal was successful—until the pandemic hit, wiping out restaurant and retail businesses. The P.F. Chang's CEO even stepped down during COVID, and Adamolekun had to 'rescue the situation,' he said. And with that, Adamolekun stepped in as CEO, officially charting his path to become a revered restaurant executive. The P.F. Chang's deal 'ended up being a really good deal, but not without a lot of blood, sweat, and tears for a few years,' Adamolekun said. He masterminded a plan to remodel the chain's restaurants and revamp the menu—and is largely using the same playbook as CEO of Red Lobster. Adamolekun, 36, took over as CEO of Red Lobster in September, as the seafood chain was crawling from the ashes of bankruptcy. He has a three-pillar roadmap for reviving Red Lobster, particularly in the aftermath of its endless-shrimp debacle. One of the biggest mistakes Red Lobster made was its endless-shrimp promotion. Because guests took advantage of the bonkers deal by consuming pound after pound of shrimp, the seafood chain ended up losing millions of dollars. So, needless to say, Adamolekun is steering clear of any future bottomless-shrimp promotions in the future. Instead, he's focused on revamping the seafood chain's menu. 'There's a lot of chain restaurants, [but] there's only one that serves lobster and crab the way we do,' Adamolekun told The Breakfast Club. The seafood chain is leaning into that differentiator, and one new crab dish has become Adamolekun's favorite. Adamolekun's master plan for reinvigorating Red Lobster includes remodeling the chain's 545 restaurants. But remodeling at that scale takes time—and money. For now, Adamolekun has implemented small changes, like changing up the music diners listen to while at the restaurant. 'We fix the things we can fix quickly,' he said during the podcast. 'The music is better.' The restaurant chain has also printed market prices for lobsters on table liners, and will continue to implement 'small things you can do now.' 'But comprehensively there needs to be a remodel…and that's something that we'll do in the future, I think,' Adamolekun said. Another cost-effective way the restaurant chain is making incremental improvements is through service and hospitality changes. Service workers are expected to greet guests more quickly and be more attentive. And Red Lobster has already seen tangible improvements from service changes. The restaurant chain tracks a sentiment score, which is a net positive versus negative sentiment, Adamolekun explained, or what people are saying is good versus bad at Red Lobster. The sentiment score was only 30 when he first took over, but last month it had doubled to 60, Adamolekun said during the podcast. 'When you go to Red Lobster next, you'll see it's going to feel different,' Adamolekun told The Breakfast Club. A version of this story originally published on on February 26, 2025. This story was originally featured on
Yahoo
6 hours ago
- Yahoo
Holyoke Stop & Shop celebrates remodel
HOLYOKE, Mass. (WWLP) – The Stop & Shop on Lincoln Street in Holyoke held its grand opening as the newly remodeled location will offer more variety for its customers. The new remodel includes a fresh new look for the produce and bakery departments as well as over 300 new products across the store. Some of which include popular Puerto Rican and Latin American favorites and Asian meal starters and marinades. Also added was an expanded grab-and-go area for prepared foods. How many families are in Massachusetts emergency housing assistance Store Manager Mark Chapdelaine spoke on what has changed inside the store, 'Produce has been greatly expanded, we have a lot more variety. We have all brand new shelving, a much cleaner look, just an easier shopping experience. I think most people would enjoy it if they came in here.' As part of the ribbon-cutting celebration, Stop & Shop will present Holyoke Community Charter School with a $15,000 check to fight food insecurity amongst students. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
Are Robust Financials Driving The Recent Rally In Orla Mining Ltd.'s (TSE:OLA) Stock?
Orla Mining's (TSE:OLA) stock is up by a considerable 60% over the past three months. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. In this article, we decided to focus on Orla Mining's ROE. Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Orla Mining is: 18% = US$89m ÷ US$507m (Based on the trailing twelve months to December 2024). The 'return' is the income the business earned over the last year. That means that for every CA$1 worth of shareholders' equity, the company generated CA$0.18 in profit. See our latest analysis for Orla Mining We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes. To begin with, Orla Mining seems to have a respectable ROE. Especially when compared to the industry average of 13% the company's ROE looks pretty impressive. This certainly adds some context to Orla Mining's exceptional 46% net income growth seen over the past five years. We believe that there might also be other aspects that are positively influencing the company's earnings growth. For instance, the company has a low payout ratio or is being managed efficiently. Next, on comparing with the industry net income growth, we found that Orla Mining's growth is quite high when compared to the industry average growth of 20% in the same period, which is great to see. Earnings growth is an important metric to consider when valuing a stock. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about Orla Mining's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry. Orla Mining doesn't pay any regular dividends to its shareholders, meaning that the company has been reinvesting all of its profits into the business. This is likely what's driving the high earnings growth number discussed above. On the whole, we feel that Orla Mining's performance has been quite good. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. That being so, a study of the latest analyst forecasts show that the company is expected to see a slowdown in its future earnings growth. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
